Edwards Lifesciences Corporation revised earnings guidance for the full year of 2022. For total Edwards, the company now expects full year 2022 sales of $5.35 to $5.55 billion. The company now expects full year adjusted EPS guidance at the bottom end of its original guidance range of $2.50 to $2.65, representing double-digit growth over 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.07 USD | -0.39% | +0.05% | +14.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.19% | 52.47B | |
+8.38% | 220B | |
+15.78% | 198B | |
+31.27% | 112B | |
+4.49% | 66.17B | |
+4.70% | 50.77B | |
-3.93% | 38.97B | |
-0.47% | 35.13B | |
+23.96% | 31.32B | |
+19.09% | 24.73B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022